HIV remains a significant health issue among children, with almost two million children living with HIV, mostly in low- and middle-income countries. Of these children, the treatment they need to survive.
In many low- and middle-income countries, people living with HIV are treated with more affordable generic versions of brand-name medications, provided through national treatment programs in the public health system.
However, children have historically been left behind adults when a new optimal generic medicine is developed and registered. They often wait decades until effective, age-appropriate formulations of the same medications become available.
Since 2016, Unitaid has funded the Clinton Health Access Initiative through its Optimal grant to bring the best HIV medications for adults and children to market more quickly and integrate them into treatment programs in communities that need them most.
In 2020, we partnered with ViiV Healthcare and two generic manufacturers to transform the process for getting a new generic HIV drug to market, called pediatric dolutegravir (DTG). What usually takes years, if not decades, was achieved in under two years.
Are you living with HIV/AIDS? Are you part of a community affected by HIV/AIDS and co-infections? Do you work or volunteer in the field? Are you motivated by our cause and interested to support our work?
Stay in the loop and get all the important EATG updates in your inbox with the EATG newsletter. The HIV & co-infections bulletin is your source of handpicked news from the field arriving regularly to your inbox.